Infrajet 25 - Omstal Pharma

This engineered variant of IGF-1 is developed for children experiencing severe growth disorders due to low IGF-1 levels, despite producing normal growth hormone. Approved in 2005 it stimulates the growth of bones, tissues, and muscles, promoting height and overall development. Administered by injection, its dosage must be carefully managed to avoid side effects like hypoglycemia, particularly when carbohydrate intake is insufficient.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Infrajet 25 by Omstal Pharma, consult with your doctor or healthcare professional.